Bio-Rad Laboratories (BIO)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Bio-Rad Laboratories (BIO)
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Key Insights
Critical company metrics and information
Share Price
$325.50Market Cap
$9.11 BillionTotal Outstanding Shares
22.92 Million SharesTotal Employees
8,030Dividend
No dividendIPO Date
February 29, 1980SIC Description
Laboratory Analytical InstrumentsHomepage
https://www.bio-rad.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $412.10 Million |
| Net Cash Flow From Financing Activities, Continuing | $-393.17 Million |
| Net Cash Flow From Operating Activities | $412.10 Million |
| Net Cash Flow From Investing Activities, Continuing | $-57.46 Million |
| Net Cash Flow From Investing Activities | $-57.46 Million |
| Net Cash Flow From Financing Activities | $-393.17 Million |
| Net Cash Flow | $-46.45 Million |
| Net Cash Flow, Continuing | $-38.54 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Benefits Costs and Expenses | $3.33 Billion |
| Gross Profit | $1.40 Billion |
| Income/Loss From Continuing Operations Before Tax | $-752.38 Million |
| Interest Expense, Operating | $49.08 Million |
| Selling, General, and Administrative Expenses | $817.19 Million |
| Operating Expenses | $1.10 Billion |
| Income Tax Expense/Benefit | $-226.50 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Income/Loss From Continuing Operations After Tax | $-778.70 Million |
| Costs And Expenses | $3.33 Billion |
| Net Income/Loss Attributable To Parent | $-778.70 Million |
| Basic Earnings Per Share | $27.74 |
| Diluted Average Shares | $28.15 Million |
| Revenues | $2.58 Billion |
| Diluted Earnings Per Share | $27.75 |
| Research and Development | $280.18 Million |
| Cost Of Revenue | $1.18 Billion |
| Net Income/Loss | $-778.70 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Net Income/Loss Available To Common Stockholders, Basic | $-778.70 Million |
| Operating Income/Loss | $305.99 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Basic Average Shares | $28.15 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $2.12 Billion |
| Inventory | $804.28 Million |
| Current Liabilities | $497.94 Million |
| Other Non-current Assets | $7.24 Billion |
| Intangible Assets | $307.32 Million |
| Liabilities And Equity | $10.60 Billion |
| Liabilities | $3.12 Billion |
| Equity Attributable To Parent | $7.49 Billion |
| Accounts Payable | $122.19 Million |
| Current Assets | $3.06 Billion |
| Noncurrent Assets | $7.55 Billion |
| Noncurrent Liabilities | $2.62 Billion |
| Equity | $7.49 Billion |
| Prepaid Expenses | $133.23 Million |
| Other Current Liabilities | $229.73 Million |
| Assets | $10.60 Billion |
| Wages | $146.02 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Related Companies
View additional S&P 500 companies similar to Bio-Rad Laboratories (BIO)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.